Scientists have identified a 14-protein blood signature that may predict lung cancer risk more than five years before ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. On the regional level, as the Human Development Index ...
Researchers have identified a blood signature that may predict lung cancer risk more than five years before diagnosis, ...
The study, published today in Cancer Cell, generated spatial transcriptomic maps in precancerous and more advanced stages of lung cancer to provide a deeper understanding of early lung cancer ...
Researchers from the University of Barcelona and the August Pi y Sunyer Biomedical Research Institute (IDIBAPS) have shown that the IGFBP3 protein plays a relevant role in human lung development. The ...
Tumor cells can lapse into a sleep-like state and thereby evade the destructive effect of cancer drugs. In some types of the ...
Scientists have identified a blood-based protein signature that can predict lung cancer risk more than five years before diagnosis. Powered by AI and validated across global datasets, the breakthrough ...
As one of the most deadly malignant tumours, lung cancer has been increasing in incidence and mortality worldwide. The incidence and mortality rates of lung cancer are increasing annually. A deeper ...
These findings from NLST and LUSI studies similarly indicate the potential role of PRISm as a useful predictor for lung cancer screening outcomes. However, as up to 73% of patients with incident lung ...
Researchers have shown that the IGFBP3 protein plays a relevant role in human lung development. The results of the study, which used organoids derived from embryonic lungs, open up new perspectives on ...
The Lung Cancer Research Foundation (LCRF), in collaboration with AstraZeneca, today announced that two research awards ...
May 13 (Reuters) - Britain's GSK (GSK.L), opens new tab and drug developer iTeos Therapeutics (ITOS.O), opens new tab said on Tuesday they have stopped developing an experimental lung cancer drug, ...